# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Scie...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 p...
Lisata Therapeutics (NASDAQ:LSTA) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $...
Brookline Capital maintains Lisata Therapeutics (NASDAQ:LSTA) with a Buy and raises the price target from $20 to $32.
Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extensionThis p...